A successful Treatment of Buprenorphine Withdrawal with the Dopamine Receptor Agonist Pramipexole

被引：5

作者：

Makhinson, Michael ^{[1
,2
]}

Gomez-Makhinson, Juliana ^{[1
,2
]}

机构：

[1] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA

[2] Harbor UCLA Med Ctr, Dept Psychiat, Torrance, CA 90509 USA

来源：

AMERICAN JOURNAL ON ADDICTIONS | 2014年 / 23卷 / 05期

关键词：

OPIATE WITHDRAWAL; OPIOID WITHDRAWAL; NUCLEUS-ACCUMBENS; MANAGEMENT; SYMPTOMS;

D O I：

10.1111/j.1521-0391.2014.12133.x

中图分类号：

R194 [卫生标准、卫生检查、医药管理];

学科分类号：

摘要：

Background: Buprenorphine, used for treating opioid dependence, may have a withdrawal syndrome requiring treatment. Modulation of the dopamine system, which has been implicated in opioid withdrawal, may be a target for withdrawal for opioids such as buprenorphine. Case Report: A case is reported of a buprenorphine withdrawal syndrome with predominant symptoms of restlessness that were resistant to clonidine and benzodiazepines. It was successfully treated with the dopamine agonist pramipexole. Scientific Significance: Dopamine receptor agonists may have a place in the treatment of restlessness associated with opioid withdrawal and may have value for the broader spectrum of opioid withdrawal symptoms.

引用

页码：475 / 477

页数：3